Publikationen, an denen er mitarbeitet Paula Olaizola Rebe (23)

2023

  1. A TGFβ-ECM-integrin signaling axis drives structural reconfiguration of the bile duct to promote polycystic liver disease

    Science translational medicine, Vol. 15, Núm. 713, pp. eabq5930

  2. A3907, a systemic ASBT inhibitor, improves cholestasis in mice by multiorgan activity and shows translational relevance to humans

    Hepatology (Baltimore, Md.), Vol. 78, Núm. 3, pp. 709-726

  3. Aberrant fucosylation sustains the NOTCH and EGFR/NF-κB pathways and has a prognostic value in human intrahepatic cholangiocarcinoma

    Hepatology (Baltimore, Md.), Vol. 78, Núm. 6, pp. 1742-1754

  4. Liquid biopsy-based protein biomarkers for risk prediction, early diagnosis, and prognostication of cholangiocarcinoma

    Journal of Hepatology, Vol. 79, Núm. 1, pp. 93-108

  5. PFKFB4 Is a Metabolic Driver of HCC Progression and Chemoresistance Through ROS Mitigation

    Cellular and Molecular Gastroenterology and Hepatology

2022

  1. Cholangiocarcinoma progression depends on the uptake and metabolization of extracellular lipids

    Hepatology, Vol. 76, Núm. 6, pp. 1617-1633

  2. Genetics, pathobiology and therapeutic opportunities of polycystic liver disease

    Nature Reviews Gastroenterology and Hepatology, Vol. 19, Núm. 9, pp. 585-604

  3. Methionine adenosyltransferase 1a antisense oligonucleotides activate the liver-brown adipose tissue axis preventing obesity and associated hepatosteatosis

    Nature Communications, Vol. 13, Núm. 1

  4. TREM-2 plays a protective role in cholestasis by acting as a negative regulator of inflammation

    Journal of Hepatology, Vol. 77, Núm. 4, pp. 991-1004

  5. Targeting NAE1-mediated protein hyper-NEDDylation halts cholangiocarcinogenesis and impacts on tumor-stroma crosstalk in experimental models

    Journal of Hepatology, Vol. 77, Núm. 1, pp. 177-190

2021

  1. FOSL1 promotes cholangiocarcinoma via transcriptional effectors that could be therapeutically targeted

    Journal of Hepatology, Vol. 75, Núm. 2, pp. 363-376

  2. Inhibition of NAE-dependent protein hyper-NEDDylation in cystic cholangiocytes halts cystogenesis in experimental models of polycystic liver disease

    United European Gastroenterology Journal, Vol. 9, Núm. 7, pp. 848-859

  3. Pathogenesis of Cholangiocarcinoma

    Annual Review of Pathology: Mechanisms of Disease, Vol. 16, pp. 433-463

  4. Targeting UBC9-mediated protein hyper-SUMOylation in cystic cholangiocytes halts polycystic liver disease in experimental models

    Journal of Hepatology, Vol. 74, Núm. 2, pp. 394-406

  5. Unscrambling a novel pathogenic role for interleukin-20 in acute hepatitis and bacterial infection: A double-edged sword?

    Journal of Hepatology

2020

  1. Lignins from agroindustrial by-products as natural ingredients for cosmetics: Chemical structure and in vitro sunscreen and cytotoxic activities

    Molecules, Vol. 25, Núm. 5

2019

  1. Antitumor Activity of a Novel Fibroblast Growth Factor Receptor Inhibitor for Intrahepatic Cholangiocarcinoma

    American Journal of Pathology, Vol. 189, Núm. 10, pp. 2090-2101

  2. Cholangiocyte-to-Hepatocyte Differentiation: A Context-Dependent Process and an Opportunity for Regenerative Medicine

    Hepatology

  3. Wnt–β-catenin signalling in liver development, health and disease

    Nature Reviews Gastroenterology and Hepatology, Vol. 16, Núm. 2, pp. 121-136

2018

  1. Differential effects of FXR or TGR5 activation in cholangiocarcinoma progression

    Biochimica et Biophysica Acta - Molecular Basis of Disease, Vol. 1864, Núm. 4, pp. 1335-1344